Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIO752 in Primary Tauopathies
NCT07868328Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Oct 2026
- Primary completion
- Mar 2029
01
Overview
A Phase 2 trial of NIO752 in progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Fronto-temporal lobar degeneration (FTLD), sponsored by Novartis. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
NIO752
03
Conditions
progressive supranuclear palsy (PSP)corticobasal degeneration (CBD)Fronto-temporal lobar degeneration (FTLD)
Beyond the preview
Go deeper on NCT07868328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07868328.